Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies

被引：11

作者：

Armstrong A.J. ^{[1
]}

Carducci M.A. ^{[1
]}

机构：

[1] Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231

来源：

Current Oncology Reports | 2005年 / 7卷 / 3期

关键词：

Prostate Cancer; Docetaxel; Mitoxantrone; Advanced Prostate Cancer; Ixabepilone;

D O I：

10.1007/s11912-005-0077-y

中图分类号：

学科分类号：

摘要：

Our understanding of the role of chemotherapy for advanced prostate cancer has improved considerably in 2004 with the publication of two large randomized phase III trials and the approval by the US Food and Drug Administration of docetaxel and prednisone for metastatic hormone-refractory disease. Although treatment is still considered palliative in nature, studies of chemotherapy for metastatic hormone-refractory prostate cancer (HRPC) have demonstrated improved overall survival compared with older regimens as well as clinically significant improvements in important endpoints, such as quality of life and time to progression. In particular, docetaxel has emerged as first-line therapy on an every-3-week schedule for metastatic HRPC, replacing mitoxantrone, as recently reported in the TAX327 trial. Docetaxel and estramustine combinations have the disadvantage of significant cardiovascular and gastrointestinal toxicity, and further use of estramustine is likely unwarranted as first-line therapy. Future trials examining novel biologic agents and combination therapies should use single-agent docetaxel as the reference standard. The role of chemotherapy for advanced disease in the neoadjuvant or adjuvant setting, in biochemically (PSA) relapsed patients, and as second-line therapy for relapsed disease, remains a subject of active clinical investigation. Copyright © 2005 by Current Science Inc.

引用

页码：220 / 227

页数：7

共 56 条

[21]

Picus J., Schultz M., Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results, Semin. Oncol., 26, 5 SUPPL. 17, pp. 14-18, (1999)

[22]

Friedland D., Cohen J., Miller R., Et al., A phase II trial of docetaxel (Taxotere) in hormone refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2, Semin. Oncol., 26, 5 SUPPL. 17, pp. 19-23, (1999)

[23]

Berry W., Rohrbaugh T., Phase II trial of single agent, weekly Taxotere in symptomatic, hormone-refractory prostate cancer, Proc. ASCO, 18, (1999)

[24]

Beer T., Pierce W., Lowe B., Et al., Phase II study of weekly docetaxel (Taxotere) in hormone refractory metastatic prostate cancer, Proc. ASCO, 19, (2000)

[25]

Ellerhorst J.A., Tu S.M., Amato R.J., Et al., Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer, Clin. Cancer Res., 3, pp. 2371-2376, (1997)

[26]

Millikan R., Thall P.F., Lee S.J., Et al., Randomized multicenter phase II trial of two multicomponent regimens in androgen-independent prostate cancer, J. Clin. Oncol., 21, pp. 878-883, (2003)

[27]

Khan M.A., Carducci M.A., Partin A.W., The evolving role of docetaxel in the management of androgen independent prostate cancer, J. Urol., 170, pp. 1709-1716, (2003)

[28]

Eymard J.C., Joly F., Priou F., Et al., Phase II randomized trial of docetaxel plus estramustine (DE) versus docetaxel (D) in patients with hormone refractory prostate cancer: A final report, Proc. ASCO, 23, (2004)

[29]

Sinibaldi V.J., Carducci M.A., Moore-Cooper S., Et al., Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma, Cancer, 94, pp. 1457-1465, (2002)

[30]

Petrylak D., Shelton G., England-Owen C., Et al., Response and preliminary survival results of a phase II study of docetaxel and estramustine in patients with androgen-independent prostate cancer, Proc. ASCO, 19, (2000)

← 1 2 3 4 5 6 →